Explores proteinopathy mapping, connecting proteotoxicity to intrinsic functions of aggregation-prone proteins, with a focus on alpha-synuclein and Parkinson's Disease.
Covers Parkinson's disease, its symptoms, diagnosis challenges, and current treatment options, emphasizing the need for early biomarkers and disease-modifying therapies.
Delves into the contrasting effects of chaperones on amyloid beta peptide aggregation, exploring inhibitors, oligomer quantification, and antibody impacts.
